Syneron's elure™ Kicks Off the Break Up. Get Even! Campaign
IRVINE, Calif., Oct. 1, 2012 /PRNewswire/ -- Syneron Medical Ltd. (NASDAQ: ELOS), www.syneron.com, the global leader in medical aesthetic products and technology, today kicked its new Break Up. Get Even! Campaign for its award winning elure™ product line. As part of the campaign, five lucky winners will get brighter and more even-toned complexion with elure's comprehensive range of products – an exclusive favorite of beauty editors. Participants can enter to win a complete elure range of products ($335 value) to BREAK UP stubborn discoloration and GET EVEN skin tone, just in time for the fall season.
Just LIKE the elure Facebook page (https://www.facebook.com/elureskin) and tell elure about your worst break up story. Include some of the dirty little details (but not too dirty!) about why this break up was memorable. And if you did something evil to get even, please dish! Without revealing names or location, we want to hear how the break up happened and what you learned from it. Share with us your thoughts on how others can avoid their worst break up ever. The contest will run for 28 days from October 1, 2012 to October 28, 2012. Winners will be announced on October 29, 2012 on Twitter @elureskin and on Facebook www.facebook.com/elureskin.
Why 28 days?
Because 28 days is all it takes to get more even toned skin with elure. Fans can vote for their favorites, so be sure to pick yours.
What is elure?
elure is the first clinically proven and professionally dispensed at home skin brightening solution developed with the natural enzyme formulation Melanozyme™, to gently yet quickly diminish the appearance of stubborn discoloration while correcting uneven skin tone to reveal a brighter, more glowing complexion for all skin types.
Earning accolades from Essence magazine and allure magazine for the elure Night Cream and allure magazine and InStyle magazine for the elure Lotion, the elure range of products consists of:
- elure Lotion: A rebalancing skin lotion with Melanozyme to brighten, soften, soothe and replenish your skin.
- elure Night Cream: Moisture rich complex with Melanozyme for a brighter and softer skin tone.
- elure Face Wash: Gentle cleanser lathers into a rich and creamy foam that removes dirt and dead skin debris to transform your skin from dull to radiant.
Follow the Break Up. Get Even! contest on Twitter @elureskin and @elurebysyneron or on Facebook at www.facebook.com/elureskin.
To enter, participants must be 18+ years old and a US resident.
About Syneron Medical Ltd.
Syneron Medical Ltd. – a company devoted to real technology, real science and real results – is the leading global aesthetic device company with a comprehensive product portfolio and a global distribution footprint. The Company's technology enables physicians to provide advanced solutions for a broad range of medical-aesthetic applications including body contouring, hair removal, wrinkle reduction, rejuvenation of the skin's appearance through the treatment of superficial benign vascular and pigmented lesions, and the treatment of acne, leg veins and cellulite. The Company sells its products under two distinct brands, Syneron and Candela. The Company's aspiration and commitment to innovation expands Syneron's offering beyond medical device into the largest in-demand applications in beauty - skin lightening. Founded in 2000, the corporate, R&D, and manufacturing headquarters for Syneron Medical Ltd. are located in Israel. Syneron also has R&D and manufacturing operations in the US. The company markets and services and supports its products in 86 countries. It has offices in North America, France, Germany, Italy, Portugal, Spain, UK, Australia, China, Japan, and Hong Kong and distributors worldwide. Additional information can be found at www.syneron.com.
SAFE HARBOR FOR FORWARD-LOOKING STATEMENTS
Any statements contained in this document regarding future expectations, beliefs, goals, plans or prospects constitute forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. Further, any statements that are not statements of historical fact (including statements containing "believes," "anticipates," "plans," "expects," "may," "will," "would," "intends," "estimates" and similar expressions) should also be considered to be forward-looking statements. There are a number of important factors that could cause actual results or events to differ materially from those indicated by such forward-looking statements, including the risk that the businesses of Syneron and Candela may not be integrated successfully; the risk that the merger transaction with Candela may involve unexpected costs or unexpected liabilities; the risk that synergies from the merger transaction may not be fully realized or may take longer to realize than expected; the risk that disruptions from the merger transaction make it more difficult to maintain relationships with customers, employees, or suppliers; as well as the risks set forth in Syneron Medical Ltd.'s most recent Annual Report on Form 20-F, and the other factors described in the filings that Syneron Medical Ltd. makes with the SEC from time to time. If one or more of these factors materialize, or if any underlying assumptions prove incorrect, Syneron Medical Ltd.'s actual results, performance or achievements may vary materially from any future results, performance or achievements expressed or implied by these forward-looking statements.
In addition, the statements in this document reflect the expectations and beliefs of Syneron Medical Ltd. as of the date of this document. Syneron Medical Ltd. anticipates that subsequent events and developments will cause its expectations and beliefs to change. However, while Syneron Medical Ltd. may elect to update these forward-looking statements publicly in the future, it specifically disclaims any obligation to do so. The forward-looking statements of Syneron Medical Ltd. do not reflect the potential impact of any future dispositions or strategic transactions that may be undertaken. These forward-looking statements should not be relied upon as representing Syneron Medical Ltd.'s views as of any date after the date of this document.
elure™ is sold as a topical cosmetic intended to beautify your skin and cosmetics are not subject to evaluation by the FDA. All product information provided is intended to be for informational purposes only. The information about skin conditions provided herein does not constitute medical or pharmaceutical advice and should not be relied upon as a substitute for qualified medical consultation with health professionals. Additional information can be found at www.syneron.com.
SOURCE Syneron Medical Ltd.
More by this Source
Syneron Medical Reports Revenue of $63.4 Million for the First Quarter 2015
13 May, 2015, 13:15 IDT
Syneron Medical to Report First Quarter 2015 Financial Results on May 13, 2015
29 Apr, 2015, 16:25 IDT
Get content for your website
Enhance your website's or blog's content with PR Newswire's customised real-time news feeds.